Table 3.
Clinical information of the two groups.
Level | High | Low | p value | |
---|---|---|---|---|
N = 170 | N = 169 | |||
Age (median [IQR]) | 64.50 [56.25, 71.75] | 69.00 [60.00, 75.00] | 0.003 | |
Gender (%) | FEMALE | 69 (40.6) | 50 (29.6) | 0.04 |
MALE | 101 (59.4) | 119 (70.4) | ||
Pathologic_T (%) | T1 | 2 (1.2) | 15 (8.9) | 0.002 |
T2 | 38 (22.4) | 35 (20.7) | ||
T3 | 75 (44.1) | 83 (49.1) | ||
T4 | 55 (32.4) | 36 (21.3) | ||
Pathologic_N (%) | N0 | 44 (26.0) | 54 (32.1) | 0.164 |
N1 | 52 (30.8) | 42 (25.0) | ||
N2 | 29 (17.2) | 39 (23.2) | ||
N3 | 44 (26.0) | 33 (19.6) | ||
Pathologic_M (%) | M0 | 150 (88.2) | 154 (91.1) | 0.046 |
M1 | 16 (9.4) | 6 (3.6) | ||
MX | 4 (2.4) | 9 (5.3) | ||
Tumor_stage (%) | stage I | 18 (11.2) | 28 (17.1) | 0.089 |
stage II | 52 (32.5) | 54 (32.9) | ||
stage III | 67 (41.9) | 71 (43.3) | ||
stage IV | 23 (14.4) | 11 (6.7) | ||
Histologic_grade (%) | G1 | 5 (2.9) | 4 (2.4) | 0.036 |
G2 | 49 (28.8) | 74 (43.8) | ||
G3 | 111 (65.3) | 87 (51.5) | ||
GX | 5 (2.9) | 4 (2.4) |